Business
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on track with established plans to accelerate patient recruitment LAWRENCEVILLE, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a trials-in-progress abstract on the ongoing Phase
About this update from Imunon, Inc.
[{"type":"image","alt":"Imunon, Inc.","displaySize":"","headline":null,"caption":"Imunon, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":290,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/512f8d6fe64afe67e274ac86630ade62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pOVE3xhQvQP6wH..j_xlsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/512f8d6fe64afe67e274ac86630ade62","width":290,"height":91}},"lazy":false},{"type":"text","content":"Prestigious European Society for Medical Oncology Conference “trials-in-progress” session","length":89,"tagName":"p"},{"type":"text","content":"Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway","length":94,"tagName":"p"},{"type":"text","content":"Company on track with established plans to accelerate patient recruitment","length":73,"tagName":"p"},{"type":"text","content":"LAWRENCEVILLE, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, was accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21, 2025 in Berlin, Germany.","length":536,"tagName":"p"},{"type":"text","content":"IMNN-001, based on IMUNON’s proprietary TheraPlas® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector incorporated in a nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment. IL-12 is a powerful pluripotent cytokine known for inducing strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation while inhibiting tumor-mediated immune suppression. IMNN-001 is the first therapy to achieve a clinically effective response in advanced (stage IIIC/IV) ovarian cancer including benefits in both progression-free survival and overall survival in a first-line treatment setting when used with standard of care chemotherapy.","length":775,"tagName":"p"},{"type":"text","content":"In July 2025...